Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial.

Jean-Louis Pujol, Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Lionel Uwer,José Hureaux,Florian Guisier,Delphine Carmier,Jeannick Madelaine,Josiane Otto,Valérie Gounant,Patrick Merle,Pierre Mourlanette,Olivier Molinier,Aldo Renault,Audrey Rabeau,Martine Antoine,Marc G Denis,Sebastien Bommart,Alexandra Langlais,Franck Morin,Pierre-Jean Souquet

Journal of Thoracic Oncology（2019）

Cited 118|Views64
No score
Abstract
Atezolizumab monotherapy in relapsed small cell lung cancer failed to demonstrate significant efficacy. No unexpected safety concerns were observed.
More
Translated text
Key words
Programmed cell death ligand 1,Atezolizumab,Chemotherapy,SCLC
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined